Analyzing Burden of Cost of Therapy in Patients Affected with Acute Coronary Syndrome in Tertiary Care Hospital

Background: The present research deals with pharmacoepidemiology and pharmacoeconomic study of Acute Coronary Syndrome (ACS) and its impact on patient’s therapeutic outcome and cost of therapy. According to a recent World Health Origination (WHO) report around 100 million people died every year due to poverty associated with illness. Contributing to the growing literature on the economic burden of illness, this article examines the indirect and direct costs of illness that occurs on household level, describes its influence on treatment seeking behavior and assesses its impact on household welfare.   Methods: The contemporary research was performed in Coronary Care Unit (CCU) and medicine ward department of medicine, RMMC and Hospital over 65 patients to illustrate the expenditure in harmony with achieved desired therapeutic outcomes by analyzing therapy cost of Acute Coronary Syndrome (ACS) supplemented via therapeutic outcomes using Minnesota Living with Heart Failure and Condition Questionnaire (MLHFCQ).   Results: The values were observed and recorded using appropriate data collection forms and MLHFC questionnaire. The total cost (TC) spent was recorded as 7,096.2 USD with most patients (n=16; 35.61%) paying in cost range of (110.1 to 141.5 USD). The total direct therapy cost was 6,278.6 USD accounting 88.47% of total cost and indirect cost 817.6 USD (11.52 % of TC). Significant improvement observed in overall mean MLHFC score of 62.93 compared to the baseline score of 37.94 rated moderate.   Conclusion: The study was designed, planned and executed to estimate cost of the given therapy and direct effect on patient therapeutic outcome.